Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EBITDA (2016 - 2025)

Historic EBITDA for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $6.9 million.

  • Gyre Therapeutics' EBITDA rose 6359.56% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 11580.63%. This contributed to the annual value of $16.2 million for FY2024, which is 12404.14% up from last year.
  • Latest data reveals that Gyre Therapeutics reported EBITDA of $6.9 million as of Q3 2025, which was up 6359.56% from $2.2 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' EBITDA peaked at $51.5 million during Q2 2022, and registered a low of -$91.6 million during Q4 2023.
  • For the 5-year period, Gyre Therapeutics' EBITDA averaged around -$6.2 million, with its median value being $2.2 million (2025).
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 34273.88% in 2021, then soared by 35876.27% in 2022.
  • Gyre Therapeutics' EBITDA (Quarter) stood at -$20.3 million in 2021, then decreased by 10.57% to -$22.5 million in 2022, then crashed by 307.98% to -$91.6 million in 2023, then skyrocketed by 100.73% to $665000.0 in 2024, then skyrocketed by 941.35% to $6.9 million in 2025.
  • Its EBITDA was $6.9 million in Q3 2025, compared to $2.2 million in Q2 2025 and $2.3 million in Q1 2025.